KPTI vs MGM · rev $68.5M vs P/E 64, rev $4.45B
Karyopharm Therapeutics Inc (KPTI) versus MGM Resorts International (MGM) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
MGM Resorts International (MGM) is a resorts & casinos company listed on NYSE.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported MGM revenue for 2026-06-30 was $4.45B. Net income was $292.4M. Revenue was down 0.1% from 2026-03-31 to 2026-06-30. MGM currently screens at market cap $12.01B and trailing P/E 64.3.
KPTI currently screens at market cap $205.6M. MGM currently screens at market cap $12.01B and trailing P/E 64.3.
Not investment advice. Open the KPTI and MGM stock pages for the full models.
Not investment advice.